Intra-Cellular Therapies, Inc. (ITCI) reported first-quarter 2024 loss of 16 cents per share, narrower than the Zacks Consensus Estimate of a loss of 31 cents, primarily due to higher product sales. The company had incurred a loss of 46 cents per share in the year-ago quarter.Total revenues, comprising product sales and grant revenues, came in at $144.9 million compared with$95.3 million reported in the year-ago period. The top line beat the Zacks Consensus Estimate of $141.9 million.Quarter in DetailCaply ...